Jerry Karabelas becomes VP-marketing of the company's U.S. prescription drug business effective June 27. Karabelas originally joined SmithKline in 1982, eventually becoming a group VP for gastrointestinal products. He left the firm in December 1989 to become CEO of Cellular Transplants Inc., a Providence, Rhode Island-based biotech firm. In his new position at SmithKline Beecham, Karabelas will replace Roger Ross, a 25-year SmithKline veteran who has decided to leave the company. The VP-marketing position currently reports to Fred Kyle, who heads U.S. pharmaceutical operations. However, the company is seeking a replacement for Kyle, who was recently given overall responsibility for worldwide manufacturing.
You may also be interested in...
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.